Navigation Links
Inflazyme Announces Outcome of Review of Phase 2b Asthma Study:,Potential Mitigating Factors Identified which Prevent Clear,Interpretation of Results

ent in their asthma independent of treatment with IPL512,602.

Finally, a large proportion of the patients were recruited during the summer allergy season, and the patients’ allergies might have diminished during the treatment phase of the trial as the allergy season waned. Resolution of allergic rhinitis could improve asthma symptoms and other measures of asthma control in all patients independent of treatment.

Our Phase 2b study was of a standard design generally used in this setting, such that these issues were not anticipated. However, taken together, we believe these issues nullify interpretation of the Phase 2b study.

Inflazyme believes that IPL512,602 would benefit from additional clinical investigation to confirm its potential as an oral treatment for asthma. The Company has significant clinical data from the earlier Phase 2a study in mild to moderate asthmatics completed by Aventis pharma (now sanofi-aventis) in June 2004, and substantial preclinical evidence indicating that the drug has efficacy in asthma. Today, Inflazyme has insufficient cash resources to conduct additional clinical trials with this product. Inflazyme plans to share these findings with other parties in an attempt to realize commercial value for this program.

About Inflazyme

Inflazyme Pharmaceuticals is a biopharmaceutical company pioneering medical breakthroughs to transform the lives of patients with respiratory and inflammatory diseases worldwide.Further information on the Company may be obtained from its website at www.inflazyme.com.

This news release contains certain “forward-looking statements” and “forward-looking information” which may include but is not limited to statements in respect of our future financial position or operations. Words like "believe", "intend", "may", "expect", “anticipate”, “plan”, “should” and oth
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/1/2014)... , August 1, 2014 ... Market by Type (Traditional Wound Closure, Anti infective), Basic ... (Artificial Skin & Skin Substitutes), Pressure Relief Devices, ... MarketsandMarkets, the global Wound Care Market is expected to ... in 2014, growing at a CAGR of 3.2% ...
(Date:8/1/2014)... Aug. 1, 2014  NxStage Medical, Inc. (Nasdaq: ... announced that Jeffrey H. Burbank , Chief Executive Officer, ... at the 34 th Annual Canaccord Genuity Growth Conference ... , on Wednesday, August 13 th at 4:30 ... available at http://ir.nxstage.com/ .  About NxStage ...
(Date:8/1/2014)... , Aug. 1, 2014  Neuland Laboratories ... active pharmaceutical ingredients (APIs), complex intermediates ... located in 85 countries, today announced financial results ... 2015, ended June 30, 2014. "Neuland,s ... work flow re-prioritization to accommodate certain customer needs, ...
Breaking Medicine Technology:Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3
... AUSTIN, Texas, May 22, 2012 SmallCapVoice.com, Inc. ... Medical Marijuana, Inc. (PINKSHEETS: MJNA) is now available. ... . Recent company activity and highlights: ... approximately $1.21 million on gross revenues of $1.79 ...
... Laboratory, Inc. (HDL, Inc.), a CAP accredited leader in ... with a non-restricted educational grant to further its mission ... the United States. In addition to the grant, HDL, ... of the 2012 Annual Scientific Sessions in Scottsdale, Arizona ...
Cached Medicine Technology:Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series 2Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series 3Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series 4Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona 2
(Date:8/1/2014)... (PRWEB) August 01, 2014 The ... (D-CA), Gregg Harper (R-MS), and Peter Welch (D-VT), ... the Medicare Telehealth Parity Act of 2014, which ... support this effort to improve healthcare access and ... executive officer of ATA. "These cost-saving provisions are ...
(Date:8/1/2014)... Market Publishers Ltd announces that in-demand ... to its catalogue. , Pharmaceutical Market ... Research and Manufacturing Services (CRAMS), Biosimilars, Generics & ... among others, increasing ageing population, rising incomes and ... pharma market in India is anticipated to emerge ...
(Date:8/1/2014)... On Monday, June 30th, the Quirk ... in San Francisco, CA. Now in its fourth year, ... Union Square hotel. , “We are excited about returning ... with ACA compliance issues,” Quirk Healthcare Foundation Executive Director, ... attendees guidance with NextGen implementation and use, electronic records ...
(Date:8/1/2014)... (HealthDay News) -- Patients with the progressive, deadly respiratory ... a new weapon to battle the disease, the U.S. ... agency approved a new treatment, an inhaled spray called ... of Americans. COPD, which is often linked to smoking, ... emphysema. Patients with COPD may experience a ...
(Date:8/1/2014)... 1, 2014 (HealthDay News) -- Although many parents worry about ... a common choking hazard: food. Such was the ... cough after eating a handful of nuts. "At the ... if the coughing was related to his illness or choking," ... cold. A cashew had become lodged in his windpipe and ...
Breaking Medicine News(10 mins):Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:FDA Approves New Treatment for People With COPD 2Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2
... Web Site Attracts,Interactive Audience, WASHINGTON, July 24 ... their menu can find more than,900 recipes at ... http://www.eatturkey.com ., (Photo: http://www.newscom.com/cgi-bin/prnh/20080724/NYFNSU04 ), ... redesigned homepage, including a,Consumer Hot Plate, for the ...
... working, reduces load on ,Social Security disability system. , ... Belleville, Ill. ... Disabilities Act on July 26, 1990, a new era began in the ... of people have gained better access to methods that help them improve ...
... age, more and more are developing dangerous health conditions such as ... medical alert bracelet jewelry gives a generation attractive incentives to display ... ... -- Baby boomers with potentially life-threatening health conditions can make a ...
... Ganey reports need for better physician-administration relations ... based on experiences of nearly 28,000 physicians, SOUTH ... Check-Up Report: Physician Perspectives on American Hospitals,finds that there ... physicians report a need for administrators to be more,responsive ...
... and CEO,of the Central Connecticut Coast YMCA, offered testimony ... Subcommittee on,Children and Families today to call for increased ... across the nation, that will,help reduce rates of obesity ... more than 2,600 YMCAs, that -- for nearly,160 years ...
... The Hanover Insurance Group,a leading super regional ... to respond to claims resulting from Hurricane Dolly, ... http://www.newscom.com/cgi-bin/prnh/20051031/NEM023LOGO ), "We are deeply ... Robin A. Nicks, president of The Hanover,s Central ...
Cached Medicine News:Health News:EatTurkey.com Gets a Healthy Upgrade 2Health News:Allsup Salutes 18th Anniversary of Americans with Disabilities Act 2Health News:Allsup Salutes 18th Anniversary of Americans with Disabilities Act 3Health News:Aging Baby Boomers Meld Life-saving Data and Style with Lauren's Hope Fashion Medical ID Bracelet 2Health News:Aging Baby Boomers Meld Life-saving Data and Style with Lauren's Hope Fashion Medical ID Bracelet 3Health News:Authoritative Report on Physician Perspectives Released Today 2Health News:YMCA Calls on Senate to Fund Community-Based Solutions to Address Childhood Obesity Crisis 2Health News:YMCA Calls on Senate to Fund Community-Based Solutions to Address Childhood Obesity Crisis 3Health News:The Hanover Ready to Serve Policyholders Impacted by Hurricane Dolly 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: